Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon
Clinical Kidney Journal · 12.12.2025 · 18 (Supplement_2) · ii26-ii34
DOI: 10.1093/ckj/sfaf322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 24.11.2025. Verfasst von Lydia Roberts und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Immunoglobulin A nephropathy (IgAN) remains the most common primary glomerulonephritis globally. Advances in mucosal immunology have illuminated the role of dysregulated B cell activity, galactose-deficient IgA1 (Gd-IgA1) and Gd-IgA1-specific antibody formation in driving disease pathogenesis. Therapeutic targeting of the mucosal immune system and, more specifically, B cell survival and differentiation pathways have entered late-stage development, offering a mechanistically guided approach to disease modification. Targeting of the gut-associated lymphoid tissue of the terminal ileum, B cell activating factor and/or a proliferation-inducing ligand antagonists and CD38-targeted agents have all demonstrated efficacy in reducing proteinuria and preserving kidney function. Emerging cellular and bispecific platforms, although early in development, raise the prospect of deeper immunologic remodelling. Precision tools such as Gd-IgA1 quantification, single-cell transcriptomics and pharmacogenomics are being explored to optimise treatment selection and duration. As real-world data and long-term safety outcomes accumulate, B cell–directed therapies are likely to become a commonly used treatment option in IgAN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Zitieren
APA
Roberts, L., & Barratt, J. (2025). Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon. Clinical Kidney Journal, 18(Supplement_2), ii26-ii34. https://doi.org/10.1093/ckj/sfaf322
Vancouver
Roberts L, Barratt J. Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon. Clinical Kidney Journal. 2025;18(Supplement_2):ii26-ii34. doi:10.1093/ckj/sfaf322
BibTeX
@article{Roberts2025,
author = {Roberts, Lydia and Barratt, Jonathan},
title = {Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon},
journal = {Clinical Kidney Journal},
year = {2025},
volume = {18},
number = {Supplement_2},
pages = {ii26--ii34},
doi = {10.1093/ckj/sfaf322}
}
EUVIMED